JP2001508457A - デング熱ウイルスのプレm/mエピトープ、合成ペプチド、キメラタンパク質およびその用途 - Google Patents
デング熱ウイルスのプレm/mエピトープ、合成ペプチド、キメラタンパク質およびその用途Info
- Publication number
- JP2001508457A JP2001508457A JP53348698A JP53348698A JP2001508457A JP 2001508457 A JP2001508457 A JP 2001508457A JP 53348698 A JP53348698 A JP 53348698A JP 53348698 A JP53348698 A JP 53348698A JP 2001508457 A JP2001508457 A JP 2001508457A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- virus
- dengue
- peptide
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 65
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 31
- 241000725619 Dengue virus Species 0.000 title claims abstract description 27
- 108020001507 fusion proteins Proteins 0.000 title description 13
- 102000037865 fusion proteins Human genes 0.000 title description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 56
- 241000700605 Viruses Species 0.000 claims abstract description 24
- 241000710831 Flavivirus Species 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 11
- 206010012310 Dengue fever Diseases 0.000 claims description 23
- 208000025729 dengue disease Diseases 0.000 claims description 23
- 101710085938 Matrix protein Proteins 0.000 claims description 22
- 101710127721 Membrane protein Proteins 0.000 claims description 22
- 208000001490 Dengue Diseases 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 230000003441 anti-flavivirus Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000710815 Dengue virus 2 Species 0.000 abstract description 15
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 15
- 230000003472 neutralizing effect Effects 0.000 abstract description 7
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 abstract 3
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 230000000890 antigenic effect Effects 0.000 description 18
- 230000003053 immunization Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 101710172711 Structural protein Proteins 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000004988 N-glycosylation Effects 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000002788 anti-peptide Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 3
- 241000710781 Flaviviridae Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101800000512 Non-structural protein 1 Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- WIGPSBHTJZUPKU-UHFFFAOYSA-N 3-benzoyl-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)C1=CC=CC=C1 WIGPSBHTJZUPKU-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 101100242961 Bos taurus SLC46A1 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000548268 Citrus deliciosa Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108700041281 Flavivirus prM Proteins 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 1
- VGALFAWDSNRXJK-VIFPVBQESA-N L-aspartic acid beta-benzyl ester Chemical compound OC(=O)[C@@H](N)CC(=O)OCC1=CC=CC=C1 VGALFAWDSNRXJK-VIFPVBQESA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001595840 Margarites Species 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001000159 Sarinda Species 0.000 description 1
- 208000009714 Severe Dengue Diseases 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003241 endoproteolytic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 125000003977 lipoyl group Chemical group S1SC(C([H])([H])C(C(C(C(=O)[*])([H])[H])([H])[H])([H])[H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.アミノ酸領域3〜31,57〜92,69〜93、および103〜124 の間で構成され、いずれかのデング熱ウィルス血清型と反応する少なくとも1つ の交差反応エピトープを含むことを特徴とするデング熱ウィルスのプレM/Mタ ンパク質に関係する合成ペプチドまたは疑似化合物。 2.アミノ酸領域3〜31,57〜92,69〜93、および103〜124 を有する、デング熱ウィルスのプレM/Mタンパク質に関係する合成ペプチドで あって、それぞれ配列表におけるペプチド19−6,19−5,20−1および 20−3であることを特徴とする請求項1記載の合成ペプチド。 3.使用されるアジュバントまたは伝達体とは関係なく、タンパク質または他 の担体に結合されているか、あるいは結合されていない、請求項1および2記載 のペプチドまたはその一部を含むことを特徴とする、抗フラビウィルス診断試薬 または製剤。 4.請求項1および2に記載の配列を認識することを特徴とするフラビウィル ス特異的抗体またはその一部。 5.請求項4記載の抗体またはその一部を含むことを特徴とする抗フラビウィ ルスワクチンまたは治療用製剤、または診断試薬。 6.アミノ酸領域1〜42および92〜134の間で構成され、担体タンパク 質に融合された、デング熱2および4ウィルスのプレM/Mタンパク質のエピト ープを含むことを特徴とする遺伝子構築物。 7.配列リストにPD31(Pre−2)、PD30(M−2)、PD34( M−4)、およびPD33(M−2/M−4)として記載される、Neisseria me ningitidisのP64kタンパク質に融合されていることを特徴とする請求項6記 載の遺伝子構築物。 8.フラビウィルスのプレM/Mタンパク質の少なくとも1つのエピトープを 含むことを特徴とする請求項6および7に記載の遺伝子構 築物。 9.請求項6,7および8に記載の少なくとも1つの遺伝子構築物の産物、ま たはその一部を含むことを特徴とする診断試薬または製剤。 10.請求項6および7に記載の配列を認識することを特徴とする抗体または 該抗体の一部分。 11.請求項10記載の抗体または該抗体の一部分を含むことを特徴とする抗 フラビウィルス製剤または診断試薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU13/97 | 1997-01-15 | ||
CU1997013A CU22683A1 (es) | 1997-01-15 | 1997-01-15 | Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos |
PCT/CU1998/000001 WO1998031814A1 (es) | 1997-01-15 | 1998-01-13 | Epitopes de la proteina pre-m/m del virus del dengue, peptidos sinteticos |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001508457A true JP2001508457A (ja) | 2001-06-26 |
JP3647048B2 JP3647048B2 (ja) | 2005-05-11 |
Family
ID=5459193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53348698A Expired - Fee Related JP3647048B2 (ja) | 1997-01-15 | 1998-01-13 | デング熱ウイルスのプレm/mエピトープ、合成ペプチド、キメラタンパク質およびその用途 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6383488B1 (ja) |
EP (1) | EP0966535B1 (ja) |
JP (1) | JP3647048B2 (ja) |
CN (1) | CN1198933C (ja) |
AT (1) | ATE284444T1 (ja) |
AU (1) | AU743414B2 (ja) |
BR (1) | BR9807486A (ja) |
CA (1) | CA2277816A1 (ja) |
CU (1) | CU22683A1 (ja) |
DE (1) | DE69828032T2 (ja) |
ES (1) | ES2235310T3 (ja) |
HK (1) | HK1025999A1 (ja) |
MY (1) | MY120971A (ja) |
NO (1) | NO993468L (ja) |
WO (1) | WO1998031814A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507864A (ja) * | 2005-09-16 | 2009-02-26 | セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア | デングウイルスのカプシドタンパク質を有する、デングウイルスに対する防御反応を誘導することができる医薬品組成物 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23245A1 (es) * | 2001-07-16 | 2007-10-17 | Inst De Medicina Tropical Pedr | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS |
AU2002356690B2 (en) * | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
EP1454988A1 (en) * | 2003-03-03 | 2004-09-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins |
US7281274B2 (en) * | 2003-10-16 | 2007-10-09 | Lmp Media Llc | Electronic media distribution system |
IN2012DN03294A (ja) * | 2004-07-27 | 2015-10-23 | Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And | |
CU23630A1 (es) | 2006-10-30 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae |
WO2009024534A2 (en) * | 2007-08-17 | 2009-02-26 | Intercell Ag | Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses |
CU20080028A6 (es) | 2008-02-29 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus |
CN108610416B (zh) * | 2008-10-13 | 2022-01-14 | 生物医学研究所 | 登革热病毒中和抗体及其用途 |
CN101921310B (zh) * | 2009-06-15 | 2014-03-12 | 温州医学院 | 登革病毒特异性hla-a2限制性表位肽及应用 |
WO2011133112A1 (en) * | 2010-04-20 | 2011-10-27 | National University Of Singapore | Cell penetrating peptide derived from the premembrane protein of flavivirus |
BR112013030637A2 (pt) * | 2011-05-26 | 2018-06-12 | Inst De Medicina Molecular | peptídeo derivado do vírus da dengue (denv) e métodos para a inibição da replicação de flavivírus |
CU24188B1 (es) * | 2012-12-27 | 2016-07-29 | Ct De Ingeniería Genética Y Biotecnología | Composición vacunal contra el virus dengue |
KR20160027019A (ko) * | 2013-06-26 | 2016-03-09 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 뎅기 바이러스 백신에 대한 방법 및 조성물 |
TWI769185B (zh) | 2016-10-27 | 2022-07-01 | 海樂源有限公司 | 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物 |
CN116082499B (zh) * | 2021-11-08 | 2023-10-27 | 东莞市朋志生物科技有限公司 | 一种抗登革ns1蛋白的抗体及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040933A1 (en) * | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
-
1997
- 1997-01-15 CU CU1997013A patent/CU22683A1/es unknown
-
1998
- 1998-01-13 CA CA002277816A patent/CA2277816A1/en not_active Abandoned
- 1998-01-13 CN CNB988032031A patent/CN1198933C/zh not_active Expired - Fee Related
- 1998-01-13 BR BR9807486A patent/BR9807486A/pt not_active Application Discontinuation
- 1998-01-13 EP EP98900843A patent/EP0966535B1/en not_active Expired - Lifetime
- 1998-01-13 AT AT98900843T patent/ATE284444T1/de not_active IP Right Cessation
- 1998-01-13 AU AU56499/98A patent/AU743414B2/en not_active Ceased
- 1998-01-13 ES ES98900843T patent/ES2235310T3/es not_active Expired - Lifetime
- 1998-01-13 DE DE69828032T patent/DE69828032T2/de not_active Expired - Fee Related
- 1998-01-13 US US09/341,833 patent/US6383488B1/en not_active Expired - Fee Related
- 1998-01-13 JP JP53348698A patent/JP3647048B2/ja not_active Expired - Fee Related
- 1998-01-13 WO PCT/CU1998/000001 patent/WO1998031814A1/es active IP Right Grant
- 1998-01-15 MY MYPI98000163A patent/MY120971A/en unknown
-
1999
- 1999-07-14 NO NO993468A patent/NO993468L/no not_active Application Discontinuation
-
2000
- 2000-08-22 HK HK00105273A patent/HK1025999A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507864A (ja) * | 2005-09-16 | 2009-02-26 | セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア | デングウイルスのカプシドタンパク質を有する、デングウイルスに対する防御反応を誘導することができる医薬品組成物 |
Also Published As
Publication number | Publication date |
---|---|
DE69828032T2 (de) | 2005-12-01 |
EP0966535A1 (en) | 1999-12-29 |
AU5649998A (en) | 1998-08-07 |
ATE284444T1 (de) | 2004-12-15 |
JP3647048B2 (ja) | 2005-05-11 |
CN1198933C (zh) | 2005-04-27 |
ES2235310T3 (es) | 2005-07-01 |
DE69828032D1 (de) | 2005-01-13 |
NO993468L (no) | 1999-09-14 |
AU743414B2 (en) | 2002-01-24 |
US6383488B1 (en) | 2002-05-07 |
MY120971A (en) | 2005-12-30 |
CN1249781A (zh) | 2000-04-05 |
WO1998031814A1 (es) | 1998-07-23 |
CA2277816A1 (en) | 1998-07-23 |
CU22683A1 (es) | 2001-07-20 |
NO993468D0 (no) | 1999-07-14 |
EP0966535B1 (en) | 2004-12-08 |
HK1025999A1 (en) | 2000-12-01 |
BR9807486A (pt) | 2000-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bray et al. | Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis | |
US8728488B2 (en) | Methods of inducing an immune response in a host by administering flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens | |
ES2237115T3 (es) | Particulas de proteinas de la envoltura del hcv: uso para la vacunacion. | |
JP3647048B2 (ja) | デング熱ウイルスのプレm/mエピトープ、合成ペプチド、キメラタンパク質およびその用途 | |
US7238356B2 (en) | Core-glycosylated HCV envelope proteins | |
EP1005363B1 (en) | Recombinant dimeric envelope vaccine against flaviviral infection | |
AU2002257392A1 (en) | Core-glycosylated hcv envelope proteins | |
KR20040030056A (ko) | 바이러스에 대한 효과를 유도하는 단백질을 코딩하는키메라 사슬 | |
WO1998023754A1 (es) | Procedimiento para la expresion de genes de los virus del dengue | |
MXPA99006629A (en) | Epitopes of the protein pre-m/m of the dengue virus, synthetic peptides | |
HRP20030946A2 (en) | Core-glycosylated hcv envelope proteins | |
MXPA00001022A (en) | Recombinant dimeric envelope vaccine against flaviviral infection | |
CZ20004802A3 (cs) | Částice obsahující obalové proteiny HCV a jejich použití pro očkování |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050208 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |